



# Second Quarter 2022

Earnings Presentation

August 3, 2022



# Forward Looking Statements

Certain statements in this presentation are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, including new variants of the virus, the pace of recovery in the markets in which we operate, global supply chain disruptions and potential staffing shortages, the conditions in the U.S. and global economy, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicity of markets we serve, the effect of the intraoral scanner acquisition on our business relationships, operating results, share price or business generally, the failure to realize the expected benefits from the intraoral scanner acquisition or the recent divestiture of our treatment unit and instrument business, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, security breaches or other disruptions of our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors, and disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2021 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentation and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

# Continued execution despite macro challenges

Delivered Core Sales Growth\* of 4.0% and Adjusted EBITDA margin\* of 19.7%

- Disciplined execution delivered MSD core sales growth, led by our Ortho and Implant businesses, while adjusted EBITDA margin\* was +40 bps vs. Q2 2021.
- The Envista Business System (EBS) helps drive short-term results while advancing our long-term strategic priorities.
- We continue to transform our portfolio. Our newly acquired IOS business is on-track to support our long-term vision of digitizing, personalizing, and democratizing dental care.

Results relate only to continuing operations except for cash flow measures.

\*Core sales growth and adjusted EBITDA margin are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

# Progress on Strategic Priorities

Transforming Envista into a higher growth and higher margin company

Priority	Results
<b>Accelerate growth through strategic organic investments</b>	<ul style="list-style-type: none"> <li>Continued strength in orthodontics; Spark core sales growth* &gt;100% vs. Q2 2021</li> <li>Implants delivered MSD core sales growth, led by Premium segment</li> <li>Innovation delivering &gt;350 bps in core sales growth* driven by Spark and Damon Ultima</li> </ul>
<b>Expand operating margins through disciplined execution and reductions in structural costs</b>	<ul style="list-style-type: none"> <li>Achieved 19.7% Adjusted EBITDA margin*; up 40 bps vs. Q2 2021</li> <li>Continue to leverage EBS to drive improvement in structural costs</li> <li>Continue to invest in long-term strategic priorities</li> </ul>
<b>Building a better, stronger, growth-oriented portfolio</b>	<ul style="list-style-type: none"> <li>Closed the acquisition of Carestream IntraOral scanner (IOS) business (Apr-22)</li> <li>Rolling out rebranding of Imaging portfolio to Dexis</li> <li>Closed the acquisition of Osteogenics regenerative solutions business (Jul-22)</li> </ul>

\*Core sales growth and adjusted EBITDA margins are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

# Q2 2022: Financial Metrics

Strong execution driving solid core sales growth\* and profitability

<b>Core Sales Growth*</b>	<b>4.0%</b>
<b>GAAP Diluted EPS</b>	<b>\$0.25</b>
<b>Adj. Diluted EPS*</b>	<b>\$0.48</b>
<b>Adjusted EBITDA*</b>	<b>\$126.9M</b>
<b>Adj. EBITDA Margin*</b>	<b>19.7%</b>
<b>Free Cash Flow*,**</b>	<b>\$11.8M</b>

- **Core Sales Growth\***
  - Solid growth despite macro challenges and delayed China re-opening
  - Specialty grew nearly 10% vs. Q2 2021
- **Profitability**
  - Solid performance, increased price and EBS-driven cost savings partially offset by inflation, increased investment in customer facing activities and long-term growth


\*Core sales growth, adjusted diluted EPS, adjusted EBITDA, adjusted EBITDA margin and free cash flow are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

\*\*Cash flow items presented include both continuing and discontinued operations.

# Specialty Products & Technologies



## Investing to accelerate long-term growth




- **Orthodontics**
  - Spark sales continue to accelerate
  - Strong growth continues in North America and Emerging Markets
  - Solid growth in core Brackets & Wires despite high PY comparison
- **Implant-based Tooth Replacements**
  - Solid growth in Premium, led by Asia and Europe
  - China implant volumes recovered quickly after re-opening
  - Accelerating growth in regenerative solutions
- **Profitability**
  - YOY margin decline driven by long-term investments in key growth initiatives and increase in customer facing activities
  - Adjusted operating margin expanded 60 bps sequentially vs. Q1 2022

\* Core sales growth and adjusted operating profit margin are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

# Equipment & Consumables

Despite top line pressure, delivered margin expansion



- **Core Sales Growth\***
  - Imaging revenue down MSD on delay in China re-opening and deteriorating market conditions in NA and EU
  - Resto/Endo down LSD in Q2 due to some destocking in the channel in North America and China lockdowns
  - Infection Prevention declined again YoY, revenue grew DD sequentially vs Q1 2022
- **Profitability**
  - Strong expansion of operating margins
  - Overall margins favorably impacted by price increases implemented across the platform

\* Core sales growth and adjusted operating profit margin are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

# Cash Flow & Balance Sheet

Strong Balance Sheet – Flexibility to continue transforming portfolio

## Free Cash Flow\*\* Summary (\$M)

	Q2'22	Q2'21
Operating cash flow*	\$22.2	\$120.7
Capital expenditures, net*	\$10.4	\$20.1
Free cash flow*,**	\$11.8	\$100.6

- **Balance Sheet**

- Ended Q2 with cash balance of >\$500 million, after finalizing Carestream Dental IOS acquisition
- Significant flexibility for capital deployment remains even after recent acquisitions

- **Free Cash Flow**

- Year over Year free cash flow impacted by transaction costs, restructuring and an increase in A/R related to order and payment patterns

\*Cash flow items presented are consolidated and include both continuing and discontinued operations.

\*\*Free cash flow is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.

# 2022 Full Year Guidance

Adjusting guidance to reflect headwinds in macro environment

Key Metric	Guidance Range
	Full Year
<b>Revenue</b>	
-Core Sales Growth	MSD
-Acquisitions (Carestream Dental's IOS + Osteogenics)	\$50 - \$60 Million
<b>Adj. EBITDA Margin</b>	<b>20%</b>

Note: These forward-looking estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as certain future gains or losses on the sale of investments, acquisition or divestiture-related gains or charges, discrete tax items and legal contingency provisions. Furthermore, please note that we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

# Summary & Key Takeaways

- ③ Dental is an attractive market with strong secular growth trends

---

- ③ Envista is strategically differentiated and has a proven track record of execution

---

- ③ Significant opportunity to accelerate growth, improve margins, & create value for patients, customers, employees, and shareholders

# Q&A

# Appendix

# Reconciliation of Adjusted Gross Profit

(\$ in Millions)

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
Gross Profit	\$ 369.8	\$ 368.6	\$ 743.9	\$ 727.0
Restructuring costs and asset impairments <sup>A</sup>	6.9	3.1	6.6	6.0
Fair value adjustment of acquisition-related inventory <sup>F</sup>	2.3	—	2.3	—
Adjusted Gross Profit	<u>\$ 379.0</u>	<u>\$ 371.7</u>	<u>\$ 752.8</u>	<u>\$ 733.0</u>
Gross Margin (Gross Profit / Sales)	57.3 %	57.8 %	58.2 %	58.2 %
Adjusted Gross Margin (Adjusted Gross Profit / Sales)	58.7 %	58.3 %	58.9 %	58.6 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# Reconciliation of Adjusted Operating Profit

(\$ in Millions)

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
<b>Consolidated</b>				
Operating Profit	\$ 65.2	\$ 83.3	\$ 156.7	178.4
Amortization of acquisition-related and other intangible assets	26.8	20.5	50.3	41.1
Restructuring costs and asset impairments <sup>A</sup>	14.8	7.4	18.5	15.2
Contingent loss reserves <sup>B</sup>	—	3.3	1.0	3.3
International tax credit <sup>C</sup>	—	—	(6.5)	—
Acquisition related expenses <sup>D</sup>	9.2	—	12.5	—
Fair value adjustment of acquisition-related inventory <sup>F</sup>	2.3	—	2.3	—
Adjusted Operating Profit	<u>\$ 118.3</u>	<u>\$ 114.5</u>	<u>\$ 234.8</u>	<u>\$ 238.0</u>
Adjusted Operating Profit as a % of Sales	18.3 %	18.0 %	18.4 %	19.0 %
<b>Specialty Products &amp; Technologies</b>				
Operating Profit	\$ 74.0	\$ 71.7	\$ 144.3	\$ 150.1
Amortization of acquisition-related and other intangible assets	14.7	15.3	29.3	30.2
Restructuring costs and asset impairments <sup>A</sup>	4.2	3.6	8.2	7.0
Contingent loss reserve <sup>B</sup>	—	2.1	1.0	2.1
International tax credit <sup>C</sup>	—	—	(1.7)	—
Adjusted Operating Profit	<u>\$ 92.9</u>	<u>\$ 92.7</u>	<u>\$ 181.1</u>	<u>\$ 189.4</u>
Adjusted Operating Profit as a % of Sales	22.8 %	24.0 %	22.5 %	25.2 %
<b>Equipment &amp; Consumables</b>				
Operating Profit	\$ 30.2	\$ 40.6	\$ 75.7	\$ 85.6
Amortization of acquisition-related and other intangible assets	12.1	5.2	21.0	10.9
Restructuring costs and asset impairments <sup>A</sup>	9.3	2.5	8.4	4.4
Contingent loss reserve <sup>B</sup>	—	1.2	—	1.2
International tax credit <sup>C</sup>	—	—	(4.8)	—
Adjusted Operating Profit	<u>\$ 51.6</u>	<u>\$ 49.5</u>	<u>\$ 100.3</u>	<u>\$ 102.1</u>
Adjusted Operating Profit as a % of Sales	21.7 %	19.7 %	21.2 %	20.5 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# Reconciliation of Adjusted Net Income

(\$ in Millions)

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
Net Income From Continuing Operations	\$ 44.5	\$ 79.0	\$ 114.9	\$ 140.8
Amortization of acquisition-related and other intangible assets	26.8	20.5	50.3	41.1
Restructuring costs and asset impairments <sup>A</sup>	14.8	7.4	18.5	15.2
Contingent loss reserves <sup>B</sup>	—	3.3	1.0	3.3
International tax credit <sup>C</sup>	—	—	(6.5)	—
Acquisition related expenses <sup>D</sup>	9.2	—	12.5	—
Non-cash interest expense - convertible senior notes <sup>E</sup>	—	4.7	—	9.3
Fair value adjustment of acquisition-related inventory <sup>F</sup>	2.3	—	2.3	—
Tax effect of adjustments reflected above <sup>G</sup>	(12.3)	(7.9)	(18.0)	(15.6)
Discrete tax adjustments and other tax-related adjustments <sup>H</sup>	0.7	(24.4)	(4.1)	(26.1)
Adjusted Net Income	\$ 86.0	\$ 82.6	\$ 170.9	\$ 168.0

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# Reconciliation of Adjusted Diluted Earnings Per Share

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
Diluted Earnings From Continuing Operations Per Share	\$ 0.25	\$ 0.44	\$ 0.64	\$ 0.79
Amortization of acquisition-related and other intangible assets	0.15	0.11	0.28	0.23
Restructuring costs and asset impairments <sup>A</sup>	0.08	0.04	0.10	0.09
Contingent loss reserves <sup>B</sup>	—	0.02	0.01	0.02
International tax credit <sup>C</sup>	—	—	(0.04)	—
Acquisition related expenses <sup>D</sup>	0.05	—	0.07	—
Non-cash interest expense - convertible senior notes <sup>E</sup>	—	0.03	—	0.05
Fair value adjustment of acquisition-related inventory <sup>F</sup>	0.01	—	0.01	—
Tax effect of adjustments reflected above <sup>G</sup>	(0.07)	(0.04)	(0.10)	(0.09)
Discrete tax adjustments and other tax-related adjustments <sup>H</sup>	0.01	(0.14)	(0.02)	(0.14)
Adjusted Diluted Earnings Per Share	\$ 0.48	\$ 0.46	\$ 0.95	\$ 0.95

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# Reconciliation of Adjusted EBITDA

(\$ in Millions)

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
Net Income From Continuing Operations	\$ 44.5	\$ 79.0	\$ 114.9	\$ 140.8
Interest expense, net	6.4	13.6	12.3	31.6
Income taxes	14.6	(9.0)	30.1	6.6
Depreciation	8.3	8.1	16.1	16.6
Amortization of acquisition-related and other intangible assets	26.8	20.5	50.3	41.1
Restructuring costs and asset impairments <sup>A</sup>	14.8	7.4	18.5	15.2
Contingent loss reserves <sup>B</sup>	—	3.3	1.0	3.3
International tax credit <sup>C</sup>	—	—	(6.5)	—
Acquisition related expenses <sup>D</sup>	9.2	—	12.5	—
Fair value adjustment of acquisition-related inventory <sup>F</sup>	2.3	—	2.3	—
<b>Adjusted EBITDA</b>	<b>\$ 126.9</b>	<b>\$ 122.9</b>	<b>\$ 251.5</b>	<b>\$ 255.2</b>
Adjusted EBITDA as a % of Sales	19.7 %	19.3 %	19.7 %	20.4 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# Reconciliation of Core Sales Growth<sup>1</sup>

	% Change Three Month Period Ended July 1, 2022 vs. Comparable 2021 Period	% Change Six Month Period Ended July 1, 2022 vs. Comparable 2021 Period
<b>Consolidated</b>		
Total sales growth	1.3 %	2.2 %
Plus the impact of:		
Acquisition	(0.9)%	(0.4)%
Currency exchange rates	3.6 %	2.9 %
Core sales growth	<u>4.0 %</u>	<u>4.7 %</u>
<b>Specialty Products &amp; Technologies</b>		
Total sales growth	5.6 %	6.9 %
Plus the impact of:		
Currency exchange rates	4.0 %	3.5 %
Core sales growth	<u>9.6 %</u>	<u>10.4 %</u>
<b>Equipment &amp; Consumables</b>		
Total sales growth	(5.1)%	(5.0)%
Plus the impact of:		
Acquisition	(2.2)%	(1.1)%
Currency exchange rates	2.6 %	2.1 %
Core sales growth	<u>(4.7)%</u>	<u>(4.0)%</u>

<sup>1</sup> We use the term “core sales” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition (“acquisitions”), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term “core sales growth” to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

# Reconciliation of Operating Cash Flows to Free Cash Flow

(\$ in Millions)

	Three Months Ended		Six Months Ended	
	July 1, 2022	July 2, 2021	July 1, 2022	July 2, 2021
Net Operating Cash Used in Investing Activities	\$ (591.6)	\$ (17.3)	\$ (586.5)	\$ (22.8)
Net Operating Cash Provided by (Used in) Financing Activities	\$ 1.8	\$ 6.5	\$ 7.1	\$ (463.1)
Net Operating Cash Provided by Operating Activities	\$ 22.2	\$ 120.7	\$ 25.7	\$ 137.3
Less: payments for additions to property, plant and equipment (capital expenditures)	(12.1)	(20.2)	(31.9)	(28.5)
Plus: proceeds from sales of property, plant and equipment (capital disposals)	1.7	0.1	1.7	0.1
Free Cash Flow	\$ 11.8	\$ 100.6	\$ (4.5)	\$ 108.9

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

# ENVISTA HOLDINGS CORPORATION

## NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

- <sup>A</sup> We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency of such plans) from the ongoing productivity improvements that result from application of the Envista Business System. These restructuring plans are incremental to the operating activities that arise in the ordinary course of our business and we believe are not indicative of Envista's ongoing operating costs in a given period.
- <sup>B</sup> Represents accruals for certain legal matters.
- <sup>C</sup> The international tax credit relates to a ruling from the Brazilian Supreme Court.
- <sup>D</sup> These represent acquisition related transactions expenses and integration costs with respect to business combinations.
- <sup>E</sup> Non-cash interest expense represents accretion of the debt discount associated with the convertible senior notes due 2025. We adopted Accounting Standards Update 2020-06 on January 1, 2022 and as a result there is no longer a debt discount that requires amortization.
- <sup>F</sup> Represents the fair value adjustment related to inventory acquired in connection with the acquisition of Carestream Dental's Intraoral Scanner Business.
- <sup>G</sup> This line item reflects the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 *Income Taxes*.
- <sup>H</sup> The discrete tax matters relate primarily to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

## Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

- with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista's business and compare Envista's profitability to prior and future periods and to Envista's peers;
- with respect to Core Sales, identify underlying growth trends in Envista's business and compare Envista's revenue performance with prior and future periods and to Envista's peers;
- with respect to Adjusted EBITDA, help investors understand operational factors associated with a company's financial performance because it excludes the following from consideration: interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts. In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and
- with respect to Free Cash Flow (the "FCF Measure"), understand Envista's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures).

## **Statement Regarding Non-GAAP Measures (Continued)**

Management uses these non-GAAP measures to measure the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

- With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA:
  - We exclude the amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly-acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
  - With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
- With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends.
- With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

# Thank You

